Nektar Therapeutics Reports Financial Results for the Third Quarter of 2015
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- S&P 500, Dow set for higher open with focus on Mideast developments
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Don’t expect a grand bargain from the Trump-Xi summit: Yardeni
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Nektar Therapeutics (NKTR) Tops Q3 EPS by 18c
November 5, 2015 4:21 PM ESTNektar Therapeutics (NASDAQ: NKTR) reported Q3 EPS of ($0.06), $0.18 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $60 million versus the consensus estimate of $44.3 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
... More